Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 2, 2017, Pages 321-331

  Savic, R M ^a   Weiner, M ^b,c   MacKenzie, W R ^d   Engle, M ^c   Whitworth, W C ^d   Johnson, J L ^e,f   Nsubuga, P ^f   Nahid, P ^g,h   Nguyen, N V ^h   Peloquin, C A ⁱ   Dooley, K E ^j   Dorman, S E ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h National Tuberculosis Program   (Viet Nam)

ⁱ UNIVERSITY OF FLORIDA HEALTH   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ABSORPTION RATE CONSTANT; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CONCENTRATION TIME CURVE; AREA UNDER THE CURVE; ARTICLE; ASIAN; BACTERICIDAL ACTIVITY; BLACK PERSON; CHRONOPHARMACOLOGY; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIET RESTRICTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; LIQUID CULTURE; LUNG CAVITY; LUNG INFILTRATE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ERROR; MEDICAL GEOGRAPHY; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METABOLISM; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS, PULMONARY;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 85014095932     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.634     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention Web site. Tuberculosis: data and statistics. . Accessed 18 September 2013.
2. Rosenthal, I.M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344 (2007).
3. Dorman, S.E. et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206, 1030–1040 (2012).
4. Dorman, S.E. et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am. J. Respir. Crit. Care Med. 191, 333–343 (2015).
5. Mitchison, D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147, 1062–1063 (1993).
6. Gler, M.T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151–2160 (2012).
7. Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528–534 (2002).
8. Merle, C.S. et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588–1598 (2014).
9. Gillespie, S.H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577–1587 (2014).
10. Horne, D.J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387–394 (2010).
11. Morse, G.D., Catanzaro, L.M. & Acosta, E.P. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6, 215–225 (2006).
12. de Kanter, C.T. et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet. 53, 409–427 (2014).
13. Kent, P.T. & Kubica, G.P. Public Health Mycobacteriology: A Guide for the Level III Laboratory. (U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, GA, 1985).
14. Zvada, S.P. et al. Effects of four different meals types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob. Agents Chemother. 54, 3390–3394 (2010).
15. Dooley, K.E. et al. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob. Agents Chemother. 59, 3399–3405 (2015).
16. Tam, C.M., Chan, S.L., Kam, K.M., Goodall, R.L. & Mitchison, D.A. Rifapentine and isoniazid in the continuation-phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int. J. Tuberc. Lung Dis. 6, 3–10 (2002).
17. Weiner, M. et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167, 1341–1347 (2003).
18. Hesseling, A.C. et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14, 560–570 (2010).
19. Hoff, D.R. et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6, e17550 (2011).
20. Rosenthal, I.M. et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56, 4331–4340 (2012).
21. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159–167 (2014).
22. Egelund, E.F. et al. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 58, 4904–4910 (2014).
23. Hasegawa, N., Miura, T., Ishizaka, A., Yamaguchi, K. & Ishii, K. Detection of mycobacteria in patients with pulmonary tuberculosis undergoing chemotherapy using MGIT and egg-based solid medium culture systems. Int. J. Tuberc. Lung Dis. 6, 447–453 (2002).
24. Chihota, V.N. et al. Liquid vs solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int. J. Tuberc. Lung Dis. 14, 1024–1031 (2010).
25. Blumberg, H.M. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603–662 (2003).
26. Savic, R.M. et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob. Agents Chemother. 58, 3035–3042 (2014).